Plus: can almonds help depression risk? DPP-4 Inhibitors & pneumonia risk; more
Can't see the images? View as webpage.
Facebook
Twitter
LinkedIn
To ensure that you never miss an issue, please whitelist us.

Saturday, Oct. 17, 2020 : Issue #1072

TOP STORIES - Diabetes News & Research

Live Longer and Cardiovascular Disease-Free

Do DPP-4 Inhibitors Increase Risk of Pneumonia in Patients with T2D?

The Positives and Negatives for Continuous Glucose Monitoring in Young Children
Letter from the Editor

As the spouse of an adult who has type 1 diabetes, I know the value of using a CGM. Just using the device gives her a sense of security and has increased her TIR immensely. However, with this technology there is an increased sense of responsibility, and there is never a time when she is not "in the know" and required to do something about it. These same feelings are often shared by children with type 1, and they have the added burden of a parent watching over them. This can become overwhelming when you add in the long future that they have with this constant "report card."

This week one of our interns, Nour Salhab, has a great article on how best to optimize CGM use in young children while avoiding burnout.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief
Advertisement

TOP STORIES - Diabetes News and Research

Live Longer and Cardiovascular Disease-Free
How many years can semaglutide add to your life?
READ MORE
Do DPP-4 Inhibitors Increase Risk of Pneumonia in Patients with T2D?
Since DPP-4 plays a role in infection for some coronaviruses, there is increased interest in whether patients using DPP-4 inhibitors are at greater pneumonia risk.
READ MORE
The Positives and Negatives for Continuous Glucose Monitoring in Young Children
CGM use in young children with type 1 diabetes has its benefits and challenges, according to their parents.
READ MORE

Did You Know: Almonds Can Reduce Depression Risk in T2D?


A bidirectional relationship is known to exist between T2DM and depression; depression increases the risk of the development of T2D, while T2D increases the risk of depression. An almond-rich diet with a low-carb diet (LCD) has been shown to reduce depression and glycometabolism in patients with T2D. According to a newly published study, the diet's impact on the gut microbiota comes from its effect. Nuts, as part of LCD, have been shown to effectively improve glycosylated hemoglobin (HbA1c) levels and fasting blood glucose (FBG) in T2DM patients. The almond is the most consumed and studied nut. Its prebiotic properties have been shown to contribute to increased production of short-chain fatty acids (SCFAs) in the gut microbiome, promoting the secretion of glucagon-like peptide 1 (GLP-1), an essential regulator of microbiota-gut-brain signaling in health and stress-related psychiatric illnesses.

A randomized controlled trial was carried out to compare the effects of an almond rich low carb diet (a-LCD) with a low-fat diet (LFD). Forty-five participants with T2DM were enrolled, and the participants completed each dietary intervention for three months. The indicators for depression and biochemical indicators, including glycosylated hemoglobin (HbA1c), gut microbiota, and GLP-1 concentration, were assessed at the baseline and third month and compared between the two groups. The resulting data revealed a low carb diet significantly improved depression and HbA1c (p <0.01). What's more, the GLP-1 concentration in the a-LCD group was higher than that in the LFD group (p <0.05). The results concluded that almonds are rich in dietary fiber, polyphenols, and unsaturated fatty acids that may be protective against the development of depression.

Nut Consumption Associated with Depressive Symptoms

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Alexandria Bartley, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences

Destiny Funchess, PharmD Candidate, Tougaloo College, South College School of Pharmacy

Aleksandra Kusic, PharmD Candidate, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences

Joan Prifti, PharmD. Candidate, LECOM College of Pharmacy 

Destiny Reed, PharmD. Candidate, Florida A&M College of Pharmacy and Pharmaceutical Sciences

Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy

Peter Jay Won, Pharm.D. Candidate, University of South Florida, Taneja College of Pharmacy

 About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com
Facebook
Twitter
LinkedIn
©2020 HIPER, LLC. All rights reserved.

This email was sent by eHealthcare Solutions on behalf of:
Diabetes In Control
810 Bear Tavern Rd, Suite 102
Ewing, NJ, 08628, United States


DiabetesInControl.com | Contact Us
Subscription Center | Update Profile
Unsubscribe